PET/CT在“Tg阳性碘-131扫描阴性”分化型甲状腺癌中的临床应用进展  

Development of Clinical Applications of PET/CT for Differentiated Thyroid Carcinoma in Patients with Negative Iodine Scan and Elevated Thyroglobulin

作　　者：张雅婧[1] 高再荣[1] 

机构地区：[1]华中科技大学协和医院核医学科,武汉430022

出　　处：《中国医疗器械信息》2011年第4期8-12,共5页China Medical Device Information

摘　　要：分化型甲状腺癌是最常见的内分泌肿瘤之一,其肿瘤组织具有吸碘能力。术后利用碘-131(I-131)全身扫描则可以探测肿瘤残余灶和转移灶,I-131治疗可以显著性降低肿瘤的复发率和转移率。而近年来因为肿瘤细胞失分化引起摄碘能力下降,约有15%的患者会出现Tg阳性而I-131全身扫描阴性,导致I-131全身扫描不能探测到肿瘤组织,I-131治疗不能发挥有效的靶向治疗作用,其进一步的治疗已成为临床上的难题,因此临床上迫切需要寻找合适的检查方法进行准确诊断。目前文献报道PET/CT对这类患者的预后评价、探测复发或转移灶有着重要的价值,本文对PET/CT在"Tg阳性碘-131扫描阴性"的分化型甲状腺癌中的临床应用进展进行了综述。Differentiated thyroid carcinoma（DTC） is the most common endocrine tumor in human with the ability to trap iodine.Iodine-131（I-131） whole-body scan（WBS） is a widely used procedure in detecting the cancer recurrence and metastasis.Radioiodine therapy has been shown to significantly reduce cancer morality,recurrence rate,and progression rate in patients with DTC.About 15 percent of DTC may lose its ability for iodine accumulation related to the occurrence of dedifferentiation of thyroid carcinoma.These carcinomas are not detected by routine 131I-WBS and can not be treated efficiently by radioiodine therapy.This subgroup of patients with negative iodine scan and elevated thyroglobulin presents clinicians with a true diagnostic dilemma,necessitating alternative imaging modalities for early detection.It is reported that FDG-PET/CT has emerged as a tool in the management of recurrent thyroid cancer.

关 键 词：分化型甲状腺癌 PET/CT 失分化 碘-131 

分 类 号：R817.4[医药卫生—影像医学与核医学]